Stromal Vascular Therapy (SVT) with AiPara Suite
Chronic, non-healing wounds (e.g., diabetic foot ulcers, venous leg ulcers)
CommercialActive
Key Facts
Indication
Chronic, non-healing wounds (e.g., diabetic foot ulcers, venous leg ulcers)
Phase
Commercial
Status
Active
Company
About Paracrine
Paracrine is a San Diego-based biotech founded in 2016, developing an integrated regenerative medicine and AI platform for chronic wound care. Its FDA 510(k)-cleared Stromal Vascular Therapy (SVT) has demonstrated a 95% wound closure rate in difficult cases, supported by the AiPara Suite for prediction, monitoring, and economic modeling. The company is commercially active across multiple international markets, positioning itself as a scalable, data-driven solution in the large and underserved global wound care market. Its business model focuses on providing the therapy and platform to clinics and health systems.
View full company profile